心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2021 CCS/CHFS心衰指南更新：定义新的射血分数降低心力衰竭药理学标准

2021-04-03 加拿大心血管学会 Can J Cardiol.2021 Apr;37(4):531-546

心力衰竭

2021年4月，加拿大心血管学会(CCS)联合加拿大心衰学会(CHFS)更新了心衰指南——定义新的射血分数降低心力衰竭药理学标准。本文主要针对射血分数降低的心衰患者的药物治疗提

中文标题：

2021 CCS/CHFS心衰指南更新：定义新的射血分数降低心力衰竭药理学标准

英文标题：

CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction

发布机构：

加拿大心血管学会

发布日期：

2021-04-03

简要介绍：

2021年4月，加拿大心血管学会(CCS)联合加拿大心衰学会(CHFS)更新了心衰指南——定义新的射血分数降低心力衰竭药理学标准。本文主要针对射血分数降低的心衰患者的药物治疗提供全面建议和实用方法。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 CCS_CHFS心衰指南更新：定义新的射血分数降低心力衰竭药理学标准.pdf)] GetToolGuiderByIdResponse(projectId=1, id=a56af1c0020895ea, title=2021 CCS/CHFS心衰指南更新：定义新的射血分数降低心力衰竭药理学标准, enTitle=CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction, guiderFrom=Can J Cardiol.2021 Apr;37(4):531-546, authorId=0, author=, summary=2021年4月，加拿大心血管学会(CCS)联合加拿大心衰学会(CHFS)更新了心衰指南&mdash;&mdash;定义新的射血分数降低心力衰竭药理学标准。本文主要针对射血分数降低的心衰患者的药物治疗提, cover=https://img.medsci.cn/2021426/1619448912572_2020535.jpg, journalId=0, articlesId=null, associationId=263, associationName=加拿大心血管学会, associationIntro=加拿大心血管学会(CCS)通过传播研究结果和最佳治疗，促进心血管健康。《加拿大心脏病学期刊》（The Canadian Journal of Cardiology,CJC）是加拿大心血管学会(Canadian Cardiovascular Society,CCS)的官方期刊。本刊面向国际，发布心脏病学与心血管病科学新知识，是加拿大心血管学研究成果与加拿大心血管学会指导方针的主要发布场所。本刊发表与心血管医学相关的临床与基础研究的原创报告、社论、评审文章、案例报告，以及关于保健结果、政策研究、道德伦理、医学历史与医学政策问题的论文。, copyright=0, guiderPublishedTime=Sat Apr 03 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年4月，加拿大心血管学会(CCS)联合加拿大心衰学会(CHFS)更新了心衰指南&mdash;&mdash;定义新的射血分数降低心力衰竭药理学标准。本文主要针对射血分数降低的心衰患者的药物治疗提供全面建议和实用方法。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=335, tagName=心力衰竭)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=335, guiderKeyword=心力衰竭, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7206, appHits=596, showAppHits=0, pcHits=1372, showPcHits=6609, likes=2, shares=39, comments=24, approvalStatus=1, publishedTime=Mon Apr 26 23:27:36 CST 2021, publishedTimeString=2021-04-03, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Apr 26 22:55:17 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 19:46:00 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 CCS_CHFS心衰指南更新：定义新的射血分数降低心力衰竭药理学标准.pdf)])
2021 CCS_CHFS心衰指南更新：定义新的射血分数降低心力衰竭药理学标准.pdf
下载请点击：
评论区 (19)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1181430, encodeId=c47c118143054, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/28DF59BFD96D1A48248EE6AED4A36C94/100, createdBy=1fc12517683, createdName=黄柠, createdTime=Thu Jan 06 19:10:40 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180484, encodeId=fbe0118048435, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/a58cd132de154a358698b0c694c6c5d6/76ce68206b51445889f5b9b093729f77.png, createdBy=f4ac1650319, createdName=1ddc6cfam23(暂无匿称), createdTime=Tue Jan 04 17:24:16 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077049, encodeId=79c210e7049f3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210729/5d08785c686c4387943d27b2b4a7bf7d/b011876b7af14bacb5649749c0c6192a.jpg, createdBy=6bb05220362, createdName=小括号, createdTime=Sun Dec 05 10:35:26 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067023, encodeId=4ba0106e0232f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1b55600265, createdName=小钟最棒, createdTime=Thu Nov 04 20:08:32 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066232, encodeId=644e106623281, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=069e5685911, createdName=ms9000000660381983, createdTime=Tue Nov 02 14:44:09 CST 2021, time=2021-11-02, status=1, ipAttribution=)]
    2022-01-06 黄柠

    好用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1181430, encodeId=c47c118143054, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/28DF59BFD96D1A48248EE6AED4A36C94/100, createdBy=1fc12517683, createdName=黄柠, createdTime=Thu Jan 06 19:10:40 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180484, encodeId=fbe0118048435, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/a58cd132de154a358698b0c694c6c5d6/76ce68206b51445889f5b9b093729f77.png, createdBy=f4ac1650319, createdName=1ddc6cfam23(暂无匿称), createdTime=Tue Jan 04 17:24:16 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077049, encodeId=79c210e7049f3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210729/5d08785c686c4387943d27b2b4a7bf7d/b011876b7af14bacb5649749c0c6192a.jpg, createdBy=6bb05220362, createdName=小括号, createdTime=Sun Dec 05 10:35:26 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067023, encodeId=4ba0106e0232f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1b55600265, createdName=小钟最棒, createdTime=Thu Nov 04 20:08:32 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066232, encodeId=644e106623281, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=069e5685911, createdName=ms9000000660381983, createdTime=Tue Nov 02 14:44:09 CST 2021, time=2021-11-02, status=1, ipAttribution=)]
    2022-01-04 1ddc6cfam23(暂无匿称)

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1181430, encodeId=c47c118143054, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/28DF59BFD96D1A48248EE6AED4A36C94/100, createdBy=1fc12517683, createdName=黄柠, createdTime=Thu Jan 06 19:10:40 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180484, encodeId=fbe0118048435, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/a58cd132de154a358698b0c694c6c5d6/76ce68206b51445889f5b9b093729f77.png, createdBy=f4ac1650319, createdName=1ddc6cfam23(暂无匿称), createdTime=Tue Jan 04 17:24:16 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077049, encodeId=79c210e7049f3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210729/5d08785c686c4387943d27b2b4a7bf7d/b011876b7af14bacb5649749c0c6192a.jpg, createdBy=6bb05220362, createdName=小括号, createdTime=Sun Dec 05 10:35:26 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067023, encodeId=4ba0106e0232f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1b55600265, createdName=小钟最棒, createdTime=Thu Nov 04 20:08:32 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066232, encodeId=644e106623281, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=069e5685911, createdName=ms9000000660381983, createdTime=Tue Nov 02 14:44:09 CST 2021, time=2021-11-02, status=1, ipAttribution=)]
    2021-12-05 小括号

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1181430, encodeId=c47c118143054, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/28DF59BFD96D1A48248EE6AED4A36C94/100, createdBy=1fc12517683, createdName=黄柠, createdTime=Thu Jan 06 19:10:40 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180484, encodeId=fbe0118048435, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/a58cd132de154a358698b0c694c6c5d6/76ce68206b51445889f5b9b093729f77.png, createdBy=f4ac1650319, createdName=1ddc6cfam23(暂无匿称), createdTime=Tue Jan 04 17:24:16 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077049, encodeId=79c210e7049f3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210729/5d08785c686c4387943d27b2b4a7bf7d/b011876b7af14bacb5649749c0c6192a.jpg, createdBy=6bb05220362, createdName=小括号, createdTime=Sun Dec 05 10:35:26 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067023, encodeId=4ba0106e0232f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1b55600265, createdName=小钟最棒, createdTime=Thu Nov 04 20:08:32 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066232, encodeId=644e106623281, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=069e5685911, createdName=ms9000000660381983, createdTime=Tue Nov 02 14:44:09 CST 2021, time=2021-11-02, status=1, ipAttribution=)]
    2021-11-04 小钟最棒

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1181430, encodeId=c47c118143054, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/28DF59BFD96D1A48248EE6AED4A36C94/100, createdBy=1fc12517683, createdName=黄柠, createdTime=Thu Jan 06 19:10:40 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180484, encodeId=fbe0118048435, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/a58cd132de154a358698b0c694c6c5d6/76ce68206b51445889f5b9b093729f77.png, createdBy=f4ac1650319, createdName=1ddc6cfam23(暂无匿称), createdTime=Tue Jan 04 17:24:16 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077049, encodeId=79c210e7049f3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210729/5d08785c686c4387943d27b2b4a7bf7d/b011876b7af14bacb5649749c0c6192a.jpg, createdBy=6bb05220362, createdName=小括号, createdTime=Sun Dec 05 10:35:26 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067023, encodeId=4ba0106e0232f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1b55600265, createdName=小钟最棒, createdTime=Thu Nov 04 20:08:32 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066232, encodeId=644e106623281, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=069e5685911, createdName=ms9000000660381983, createdTime=Tue Nov 02 14:44:09 CST 2021, time=2021-11-02, status=1, ipAttribution=)]
    2021-11-02 ms9000000660381983

    学习

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2021 HFA/EACVI/EHRA/EAPCI立场声明：心力衰竭患者继发二尖瓣反流的管理

欧洲心力衰竭协会(HFA,Heart Failure Association) · 2021-03-18

房间隔分流器治疗射血分数保留心力衰竭：中国专家认识和建议

中国医师协会心血管内科医师分会(CCCP,Chinese College of Cardiovascular Physicians) · 2020-12-30

2021 法国专家共识：高龄患者心力衰竭的管理

法国老年学及老年病学学会(FSGG,French Society of Gerontology and Geriatrics) · 2021-01-14

2020心肌梗死后心力衰竭防治专家共识

中国医师协会心血管内科医师分会(CCCP,Chinese College of Cardiovascular Physicians) · 2020-12-30

2021 ACC专家共识决策路径：优化心力衰竭的治疗（更新版）

美国心脏病学会(ACC,American College of Cardiology) · 2021-01-11

舒张性心力衰竭早期防治专家建议

中国心血管相关专家小组（统称） · 2020-12-30

拓展阅读

2010 中华医学会 急性心力衰竭诊断和治疗指南

中华医学会心血管病学分会(Chinese Society of Cardiology) · 2010-01-01

心脏再同步治疗慢性心力衰竭的建议（2009年修订版）

中华医学会心电生理和起搏分会 · 2010-02-25

加拿大心衰诊疗指南（2010更新）：少数民族人口，心脏衰竭和怀孕，疾病管理，和质量改进/保证方案心力衰竭

加拿大心血管学会(CCS,Canadian Cardiovascular Society) · 2010-04-01

2010HFSA 心力衰竭治疗指南

美国心衰学会(HFSA,HEART FAILURE SOCIETY OF AMERICA) · 2010-07-01

2011AHA/ACC 急性心力衰竭综合征：急诊科表现、治疗、处置的现状及预期目的--来自美国心脏病协会科学声明

美国心脏协会(AHA,American Heart Association) · 2011-04-14

2012AHA 科学声明：心力衰竭诊疗进展科学决策

美国心脏协会(AHA,American Heart Association) · 2012-03-05